Drug Profile
CKD 506
Alternative Names: CKD506Latest Information Update: 31 Aug 2022
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 01 Feb 2022 Chong Kun Dang Pharmaceutical initiates a phase I drug-drug interaction trial in Healthy volunteers (NCT05238948)
- 14 Apr 2021 CKD 506 is available for licensing as of 14 Apr 2021. http://www.ckdpharm.com/en/etc/contact.do
- 17 Mar 2021 Phase II development is still ongoing for Inflammatory bowel diseases and Rheumatoid arthritis in European Union (Chong Kun Dang pipeline, March 2021)